APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bradykinin Receptor Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Bradykinin Receptor Antagonists Market Outlook and Growth Opportunities 2026

29 December 2025192 pages

Choose your research edition.

Industry ResearchBradykinin Receptor Antagonists Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Bradykinin Receptor Antagonists Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Bradykinin Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bradykinin Receptor Antagonists Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Bradykinin Receptor Antagonists Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Bradykinin Receptor Antagonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Bradykinin Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Bradykinin Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Bradykinin Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Bradykinin Receptor Antagonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Bradykinin Receptor Antagonists market include Takeda Pharmaceuticals, Sandoz, Jiangsu Hengrui Pharmaceuticals, Chengdu Shengnuo Biology Pharmacy, Glenmark Pharmaceuticals, Fresenius Kabi, Eugia Pharma Specialities and Cipla, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Bradykinin Receptor Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Bradykinin Receptor Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Bradykinin Receptor Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Bradykinin Receptor Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.

Bradykinin Receptor Antagonists Segment by Company

Takeda Pharmaceuticals

Sandoz

Jiangsu Hengrui Pharmaceuticals

Chengdu Shengnuo Biology Pharmacy

Glenmark Pharmaceuticals

Fresenius Kabi

Eugia Pharma Specialities

Cipla

Bradykinin Receptor Antagonists Segment by Type

Icatibant

Other

Bradykinin Receptor Antagonists Segment by Application

Hospital and Clinic

Pharmacy

Other

Bradykinin Receptor Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Bradykinin Receptor Antagonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Bradykinin Receptor Antagonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Bradykinin Receptor Antagonists significant trends, drivers, influence factors in global and regions.

6. To analyze Bradykinin Receptor Antagonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bradykinin Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bradykinin Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bradykinin Receptor Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Bradykinin Receptor Antagonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Bradykinin Receptor Antagonists industry.

Chapter 3: Detailed analysis of Bradykinin Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Bradykinin Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Bradykinin Receptor Antagonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Bradykinin Receptor Antagonists Industry Trends Table 2. Bradykinin Receptor Antagonists Industry Drivers Table 3. Bradykinin Receptor Antagonists Industry Opportunities and Challenges Table 4. Bradykinin Receptor Antagonists Industry Restraints Table 5. Global Bradykinin Receptor Antagonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Bradykinin Receptor Antagonists Revenue Share by Company (2021-2026) Table 7. Global Bradykinin Receptor Antagonists Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Bradykinin Receptor Antagonists Sales Volume Share by Company (2021-2026) Table 9. Global Bradykinin Receptor Antagonists Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Bradykinin Receptor Antagonists Company Ranking, (2024-2026) & (USD Million) Table 11. Global Bradykinin Receptor Antagonists Key Company Manufacturing Base & Headquarters Table 12. Global Bradykinin Receptor Antagonists Company, Product Type & Application Table 13. Global Bradykinin Receptor Antagonists Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Bradykinin Receptor Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Icatibant Table 18. Significant Companies of Other Table 19. Global Bradykinin Receptor Antagonists Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Bradykinin Receptor Antagonists Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Bradykinin Receptor Antagonists Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Bradykinin Receptor Antagonists Sales Volume Share by Type (2021-2026) Table 23. Global Bradykinin Receptor Antagonists Sales Volume Share by Type (2027-2032) Table 24. Global Bradykinin Receptor Antagonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Bradykinin Receptor Antagonists Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Bradykinin Receptor Antagonists Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Bradykinin Receptor Antagonists Sales Value Share by Type (2021-2026) Table 28. Global Bradykinin Receptor Antagonists Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital and Clinic Table 30. Significant Companies of Pharmacy Table 31. Significant Companies of Other Table 32. Global Bradykinin Receptor Antagonists Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Bradykinin Receptor Antagonists Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Bradykinin Receptor Antagonists Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Bradykinin Receptor Antagonists Sales Volume Share by Application (2021-2026) Table 36. Global Bradykinin Receptor Antagonists Sales Volume Share by Application (2027-2032) Table 37. Global Bradykinin Receptor Antagonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Bradykinin Receptor Antagonists Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Bradykinin Receptor Antagonists Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Bradykinin Receptor Antagonists Sales Value Share by Application (2021-2026) Table 41. Global Bradykinin Receptor Antagonists Sales Value Share by Application (2027-2032) Table 42. Global Bradykinin Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Bradykinin Receptor Antagonists Sales by Region (2021-2026) & (K Units) Table 44. Global Bradykinin Receptor Antagonists Sales Market Share by Region (2021-2026) Table 45. Global Bradykinin Receptor Antagonists Sales by Region (2027-2032) & (K Units) Table 46. Global Bradykinin Receptor Antagonists Sales Market Share by Region (2027-2032) Table 47. Global Bradykinin Receptor Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Bradykinin Receptor Antagonists Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Bradykinin Receptor Antagonists Sales Value Share by Region (2021-2026) Table 50. Global Bradykinin Receptor Antagonists Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Bradykinin Receptor Antagonists Sales Value Share by Region (2027-2032) Table 52. Global Bradykinin Receptor Antagonists Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Bradykinin Receptor Antagonists Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Bradykinin Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Bradykinin Receptor Antagonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Bradykinin Receptor Antagonists Sales by Country (2021-2026) & (K Units) Table 57. Global Bradykinin Receptor Antagonists Sales Market Share by Country (2021-2026) Table 58. Global Bradykinin Receptor Antagonists Sales by Country (2027-2032) & (K Units) Table 59. Global Bradykinin Receptor Antagonists Sales Market Share by Country (2027-2032) Table 60. Global Bradykinin Receptor Antagonists Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Bradykinin Receptor Antagonists Sales Value Market Share by Country (2021-2026) Table 62. Global Bradykinin Receptor Antagonists Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Bradykinin Receptor Antagonists Sales Value Market Share by Country (2027-2032) Table 64. Takeda Pharmaceuticals Company Information Table 65. Takeda Pharmaceuticals Business Overview Table 66. Takeda Pharmaceuticals Bradykinin Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Takeda Pharmaceuticals Bradykinin Receptor Antagonists Product Portfolio Table 68. Takeda Pharmaceuticals Recent Development Table 69. Sandoz Company Information Table 70. Sandoz Business Overview Table 71. Sandoz Bradykinin Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Sandoz Bradykinin Receptor Antagonists Product Portfolio Table 73. Sandoz Recent Development Table 74. Jiangsu Hengrui Pharmaceuticals Company Information Table 75. Jiangsu Hengrui Pharmaceuticals Business Overview Table 76. Jiangsu Hengrui Pharmaceuticals Bradykinin Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Jiangsu Hengrui Pharmaceuticals Bradykinin Receptor Antagonists Product Portfolio Table 78. Jiangsu Hengrui Pharmaceuticals Recent Development Table 79. Chengdu Shengnuo Biology Pharmacy Company Information Table 80. Chengdu Shengnuo Biology Pharmacy Business Overview Table 81. Chengdu Shengnuo Biology Pharmacy Bradykinin Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Chengdu Shengnuo Biology Pharmacy Bradykinin Receptor Antagonists Product Portfolio Table 83. Chengdu Shengnuo Biology Pharmacy Recent Development Table 84. Glenmark Pharmaceuticals Company Information Table 85. Glenmark Pharmaceuticals Business Overview Table 86. Glenmark Pharmaceuticals Bradykinin Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Glenmark Pharmaceuticals Bradykinin Receptor Antagonists Product Portfolio Table 88. Glenmark Pharmaceuticals Recent Development Table 89. Fresenius Kabi Company Information Table 90. Fresenius Kabi Business Overview Table 91. Fresenius Kabi Bradykinin Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Fresenius Kabi Bradykinin Receptor Antagonists Product Portfolio Table 93. Fresenius Kabi Recent Development Table 94. Eugia Pharma Specialities Company Information Table 95. Eugia Pharma Specialities Business Overview Table 96. Eugia Pharma Specialities Bradykinin Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Eugia Pharma Specialities Bradykinin Receptor Antagonists Product Portfolio Table 98. Eugia Pharma Specialities Recent Development Table 99. Cipla Company Information Table 100. Cipla Business Overview Table 101. Cipla Bradykinin Receptor Antagonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Cipla Bradykinin Receptor Antagonists Product Portfolio Table 103. Cipla Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Bradykinin Receptor Antagonists Distributors List Table 107. Bradykinin Receptor Antagonists Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Bradykinin Receptor Antagonists Product Image Figure 2. Global Bradykinin Receptor Antagonists Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bradykinin Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 4. Global Bradykinin Receptor Antagonists Sales (2021-2032) & (K Units) Figure 5. Global Bradykinin Receptor Antagonists Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Bradykinin Receptor Antagonists Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Icatibant Image Figure 10. Other Image Figure 11. Global Bradykinin Receptor Antagonists Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Bradykinin Receptor Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Bradykinin Receptor Antagonists Sales Volume Share by Type (2021-2032) Figure 14. Global Bradykinin Receptor Antagonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Bradykinin Receptor Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Bradykinin Receptor Antagonists Sales Value Share by Type (2021-2032) Figure 17. Hospital and Clinic Image Figure 18. Pharmacy Image Figure 19. Other Image Figure 20. Global Bradykinin Receptor Antagonists Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Bradykinin Receptor Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Bradykinin Receptor Antagonists Sales Volume Share by Application (2021-2032) Figure 23. Global Bradykinin Receptor Antagonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Bradykinin Receptor Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Bradykinin Receptor Antagonists Sales Value Share by Application (2021-2032) Figure 26. Global Bradykinin Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Bradykinin Receptor Antagonists Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Bradykinin Receptor Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Bradykinin Receptor Antagonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Bradykinin Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 31. North America Bradykinin Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Bradykinin Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Bradykinin Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Bradykinin Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Bradykinin Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Bradykinin Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 37. South America Bradykinin Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Bradykinin Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Bradykinin Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Bradykinin Receptor Antagonists Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Bradykinin Receptor Antagonists Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Icatibant
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Takeda Pharmaceuticals
  • Sandoz
  • Jiangsu Hengrui Pharmaceuticals
  • Chengdu Shengnuo Biology Pharmacy
  • Glenmark Pharmaceuticals
  • Fresenius Kabi
  • Eugia Pharma Specialities
  • Cipla

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Bradykinin Receptor Antagonists Sales Value (2021-2032)
  4. 1.2.2 Global Bradykinin Receptor Antagonists Sales Volume (2021-2032)
  5. 1.2.3 Global Bradykinin Receptor Antagonists Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Bradykinin Receptor Antagonists Market Dynamics
  1. 2.1 Bradykinin Receptor Antagonists Industry Trends
  2. 2.2 Bradykinin Receptor Antagonists Industry Drivers
  3. 2.3 Bradykinin Receptor Antagonists Industry Opportunities and Challenges
  4. 2.4 Bradykinin Receptor Antagonists Industry Restraints
3 Bradykinin Receptor Antagonists Market by Company
  1. 3.1 Global Bradykinin Receptor Antagonists Company Revenue Ranking in 2025
  2. 3.2 Global Bradykinin Receptor Antagonists Revenue by Company (2021-2026)
  3. 3.3 Global Bradykinin Receptor Antagonists Sales Volume by Company (2021-2026)
  4. 3.4 Global Bradykinin Receptor Antagonists Average Price by Company (2021-2026)
  5. 3.5 Global Bradykinin Receptor Antagonists Company Ranking (2024-2026)
  6. 3.6 Global Bradykinin Receptor Antagonists Company Manufacturing Base and Headquarters
  7. 3.7 Global Bradykinin Receptor Antagonists Company Product Type and Application
  8. 3.8 Global Bradykinin Receptor Antagonists Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Bradykinin Receptor Antagonists Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Bradykinin Receptor Antagonists Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Bradykinin Receptor Antagonists Market by Type
  1. 4.1 Bradykinin Receptor Antagonists Type Introduction
  2. 4.1.1 Icatibant
  3. 4.1.2 Other
  4. 4.2 Global Bradykinin Receptor Antagonists Sales Volume by Type
  5. 4.2.1 Global Bradykinin Receptor Antagonists Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Bradykinin Receptor Antagonists Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Bradykinin Receptor Antagonists Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Bradykinin Receptor Antagonists Sales Value by Type
  9. 4.3.1 Global Bradykinin Receptor Antagonists Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Bradykinin Receptor Antagonists Sales Value by Type (2021-2032)
  11. 4.3.3 Global Bradykinin Receptor Antagonists Sales Value Share by Type (2021-2032)
5 Bradykinin Receptor Antagonists Market by Application
  1. 5.1 Bradykinin Receptor Antagonists Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Bradykinin Receptor Antagonists Sales Volume by Application
  6. 5.2.1 Global Bradykinin Receptor Antagonists Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Bradykinin Receptor Antagonists Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Bradykinin Receptor Antagonists Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Bradykinin Receptor Antagonists Sales Value by Application
  10. 5.3.1 Global Bradykinin Receptor Antagonists Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Bradykinin Receptor Antagonists Sales Value by Application (2021-2032)
  12. 5.3.3 Global Bradykinin Receptor Antagonists Sales Value Share by Application (2021-2032)
6 Bradykinin Receptor Antagonists Regional Sales and Value Analysis
  1. 6.1 Global Bradykinin Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Bradykinin Receptor Antagonists Sales by Region (2021-2032)
  3. 6.2.1 Global Bradykinin Receptor Antagonists Sales by Region: 2021-2026
  4. 6.2.2 Global Bradykinin Receptor Antagonists Sales by Region (2027-2032)
  5. 6.3 Global Bradykinin Receptor Antagonists Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Bradykinin Receptor Antagonists Sales Value by Region (2021-2032)
  7. 6.4.1 Global Bradykinin Receptor Antagonists Sales Value by Region: 2021-2026
  8. 6.4.2 Global Bradykinin Receptor Antagonists Sales Value by Region (2027-2032)
  9. 6.5 Global Bradykinin Receptor Antagonists Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Bradykinin Receptor Antagonists Sales Value (2021-2032)
  12. 6.6.2 North America Bradykinin Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Bradykinin Receptor Antagonists Sales Value (2021-2032)
  15. 6.7.2 Europe Bradykinin Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Bradykinin Receptor Antagonists Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Bradykinin Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Bradykinin Receptor Antagonists Sales Value (2021-2032)
  21. 6.9.2 South America Bradykinin Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Bradykinin Receptor Antagonists Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Bradykinin Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
7 Bradykinin Receptor Antagonists Country-level Sales and Value Analysis
  1. 7.1 Global Bradykinin Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Bradykinin Receptor Antagonists Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Bradykinin Receptor Antagonists Sales by Country (2021-2032)
  4. 7.3.1 Global Bradykinin Receptor Antagonists Sales by Country (2021-2026)
  5. 7.3.2 Global Bradykinin Receptor Antagonists Sales by Country (2027-2032)
  6. 7.4 Global Bradykinin Receptor Antagonists Sales Value by Country (2021-2032)
  7. 7.4.1 Global Bradykinin Receptor Antagonists Sales Value by Country (2021-2026)
  8. 7.4.2 Global Bradykinin Receptor Antagonists Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Bradykinin Receptor Antagonists Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Bradykinin Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Bradykinin Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Bradykinin Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Bradykinin Receptor Antagonists Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Sandoz
  8. 8.2.1 Sandoz Company Information
  9. 8.2.2 Sandoz Business Overview
  10. 8.2.3 Sandoz Bradykinin Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sandoz Bradykinin Receptor Antagonists Product Portfolio
  12. 8.2.5 Sandoz Recent Developments
  13. 8.3 Jiangsu Hengrui Pharmaceuticals
  14. 8.3.1 Jiangsu Hengrui Pharmaceuticals Company Information
  15. 8.3.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  16. 8.3.3 Jiangsu Hengrui Pharmaceuticals Bradykinin Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Jiangsu Hengrui Pharmaceuticals Bradykinin Receptor Antagonists Product Portfolio
  18. 8.3.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  19. 8.4 Chengdu Shengnuo Biology Pharmacy
  20. 8.4.1 Chengdu Shengnuo Biology Pharmacy Company Information
  21. 8.4.2 Chengdu Shengnuo Biology Pharmacy Business Overview
  22. 8.4.3 Chengdu Shengnuo Biology Pharmacy Bradykinin Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Chengdu Shengnuo Biology Pharmacy Bradykinin Receptor Antagonists Product Portfolio
  24. 8.4.5 Chengdu Shengnuo Biology Pharmacy Recent Developments
  25. 8.5 Glenmark Pharmaceuticals
  26. 8.5.1 Glenmark Pharmaceuticals Company Information
  27. 8.5.2 Glenmark Pharmaceuticals Business Overview
  28. 8.5.3 Glenmark Pharmaceuticals Bradykinin Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Glenmark Pharmaceuticals Bradykinin Receptor Antagonists Product Portfolio
  30. 8.5.5 Glenmark Pharmaceuticals Recent Developments
  31. 8.6 Fresenius Kabi
  32. 8.6.1 Fresenius Kabi Company Information
  33. 8.6.2 Fresenius Kabi Business Overview
  34. 8.6.3 Fresenius Kabi Bradykinin Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Fresenius Kabi Bradykinin Receptor Antagonists Product Portfolio
  36. 8.6.5 Fresenius Kabi Recent Developments
  37. 8.7 Eugia Pharma Specialities
  38. 8.7.1 Eugia Pharma Specialities Company Information
  39. 8.7.2 Eugia Pharma Specialities Business Overview
  40. 8.7.3 Eugia Pharma Specialities Bradykinin Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Eugia Pharma Specialities Bradykinin Receptor Antagonists Product Portfolio
  42. 8.7.5 Eugia Pharma Specialities Recent Developments
  43. 8.8 Cipla
  44. 8.8.1 Cipla Company Information
  45. 8.8.2 Cipla Business Overview
  46. 8.8.3 Cipla Bradykinin Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Cipla Bradykinin Receptor Antagonists Product Portfolio
  48. 8.8.5 Cipla Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Bradykinin Receptor Antagonists Value Chain Analysis
  2. 9.1.1 Bradykinin Receptor Antagonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Bradykinin Receptor Antagonists Sales Mode & Process
  6. 9.2 Bradykinin Receptor Antagonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Bradykinin Receptor Antagonists Distributors
  9. 9.2.3 Bradykinin Receptor Antagonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst